research use only
Cat.No.S5023
|
In vitro |
DMSO
: 61 mg/mL
(197.15 mM)
|
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 309.40 | Formula | C17H27NO4 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 42200-33-9 | -- | Storage of Stock Solutions |
|
|
| Synonyms | Corgard, Solgol, Anabet, SQ11725 | Smiles | CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O | ||
| Targets/IC50/Ki |
β-adrenergic receptor
|
|---|---|
| In vitro |
Nadolol is a new beta-adrenoceptor blocking agent without intrinsic sympathomimetic action and with an extremely long plasma half life. This compound antagonizes isoproterenol-induced tachycardia and ouabain-induced arrhythmias in cats, antagonizes coronary artery ligation-induced ventricular fibrillation and suppresses ventricular ectopic activity during vagal stimulation in dogs.
|
| In vivo |
In several experimental models (mongrel cats and mongrel dogs), nadolol is effective against cardiac arrhythmias. This anti-arrhythmic activity appears to be related to fi-adrenergic receptor blockade, an action that would antagonize the ability of catecholamines to induce arrhythmias by alteration of cardiac automaticity and conductivity. It is also effective in preventing ventricular fibrillation induced by ligation of the left anterior descending coronary artery. This compound has been demonstrated to have a half-life of 4 to 5 hr in animals. It does not block neuromuscular transmission at the junction of the vagus and heart. Furthermore, this chemical does not depress excitability of the heart, as demonstrated by the lack of effect on diastolic threshold in the intact heart of the dog. It is rapidly absorbed from the gastrointestinal tract and remarkalely well-tolerated when given in extremely large doses.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01010308 | Completed | Infantile Hemangioma |
The Hospital for Sick Children |
November 2009 | Phase 2 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.